Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS

OBJECTIVE: This phase I study investigated pharmacokinetic (PK) and pharmacodynamic (PD) profiles of natalizumab in pediatric patients with relapsing-remitting MS (RRMS). METHODS: Pediatric patients with RRMS who were prescribed natalizumab 300 mg IV every 4 weeks were enrolled. Blood samples were c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghezzi, Angelo, Comi, Giancarlo, Grimaldi, Luigi Maria, Moiola, Lucia, Pozzilli, Carlo, Fantaccini, Simone, Gallo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624146/
https://www.ncbi.nlm.nih.gov/pubmed/31355324
http://dx.doi.org/10.1212/NXI.0000000000000591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624146/
https://www.ncbi.nlm.nih.gov/pubmed/31355324
http://dx.doi.org/10.1212/NXI.0000000000000591

Ejemplares similares